News

EU takes action against fake meds
Enlarge image

CommercialisationEU

EU takes action against fake meds

10.02.2016 - In future, meds will come in packages sporting a unique barcode and an anti-tampering device. These measures are part of the EU’s new regulation to safeguard against falsified medicines.

The Falsified Medicines Directive was published on Tuesday in the Official Journal of the European Union, after being adopted in October last year. It introduces a new medicine verification system on the packaging of medicines for human use. “Directive 2011/62/EU introduces obligatory ‘safety features’ – a unique identifier and an anti-tampering device - to allow the verification of the authenticity of medicinal products subject to prescription and protect patients and business alike from the risks of falsified medicines”, states the European Commission. To guide drug marketers, the European Medicines Agency and the European Commission have prepared an implementation plan (PDF) for centrally authorised medicines. The marketing-authorisation holders have until February 2019 to bring the new safety features in place.

Falsified medicines pass themselves off as the real thing, while being anything but. Fake meds have been found to contain ingredients that are of bad quality or wrongly dosed. They are a “major threat to public health”, the European Commission points out. In 2011, the EU adopted a new directive on falsified medicines for human use. However, as falsifications become more sophisticated, new measures are necessary to keep phony meds off the market. 

 

© european-biotechnology-news.com/um

http://www.european-biotechnology-news.com/news/news/2016-01/eu-takes-action-against-fake-meds.html

Clinical ResearchFrancePortugalEU

05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.

M&ASwitzerland

04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.

FinancingEUUKBelgium

01.02.2016 Newly formed Medicxi Ventures, a life sciences-dedicated VC firm based in London, Geneva and Jersey, has closed a €210m investment fund to reinvest in European early-stage assets.

ResearchUKEU

01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.

M&ASwedenIceland

28.01.2016 Swedish infectious disease specialist Enzymatica has bagged Icelandic company Zymetech, who produces the patent-protected enzyme used in Enzymatica’s own common cold blocker ColdZyme.

R&DUK

27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.

Clinical TrialsGermany

25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.

AMREU

21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.

M&AFinland

19.01.2016 Biotie Therapies has long been expanding its business in the US. Now, the Finnish company is set to be taken over by US company Acorda Therapeutics, which is paying €321m for the shares.

© 2007-2016 BIOCOM

http://www.european-biotechnology-news.com/news/news/pos/4.html

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SAREUM HOLDINGS (UK)0.28 GBP12.00%
  • IXICO (UK)35.50 GBP4.41%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • THERAMETRICS (CH)0.04 CHF-20.00%

TOP

  • VERONA PHARMA (UK)3.25 GBP22.6%
  • IXICO (UK)35.50 GBP20.3%
  • SERODUS (N)2.55 NOK10.9%

FLOP

  • BIONOR PHARMA (N)0.80 NOK-53.5%
  • PROTHENA PLC (IE)30.94 USD-36.1%
  • ZEALAND PHARMA (DK)92.50 DKK-34.6%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)24.00 SEK3016.9%
  • 4SC (D)3.04 EUR261.9%

FLOP

  • BIOTEST (D)11.91 EUR-87.1%
  • NEUROVIVE PHARMACEUTICAL AB (S)8.70 SEK-85.7%
  • EVOCUTIS (UK)0.08 GBP-71.4%

No liability assumed, Date: 10.02.2016